Brain, Etienne
Chen, Connie
Simon, Sofia
Pasupuleti, Vinay
Pfitzer, Kathleen Vieira
Gelmon, Karen A. http://orcid.org/0000-0003-4111-2757
Funding for this research was provided by:
Pfizer Inc.
Article History
Accepted: 23 February 2024
First Online: 28 March 2024
Declarations
:
: This review was funded by Pfizer Inc.
: Etienne Brain has served as a consultant/advisor for Daiichi, Menarini, Pfizer Inc., and Sandoz; has received honoraria from Pfizer Inc., Eli Lilly, Incyte, and Seagen; has received travel support from Gilead, Pfizer Inc., AstraZeneca, and Novartis; and served on an advisory board for Daiichi. Connie Chen and Sofia Simon are employees of Pfizer Inc. Vinay Pasupuleti is an employee of Oxford PharmaGenesis Inc. Kathleen Vieira Pfitzer has no conflicts of interest to disclose. Karen A. Gelmon has served on an advisory board for Pfizer Inc, Novartis, Eli Lilly, Merck, Gilead, Seagan, Astra Zeneca, and City of Hope.
: No new data were created or analyzed during this study. Data sharing is not applicable to this article.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: EB, CC, SF, VP, and KAG contributed to study conceptualization and design. CC, SF, and VP conducted the literature review and prepared the first draft of the manuscript. All authors reviewed, revised, and provided critical feedback on the manuscript. All authors provided final approval of the manuscript.